Accelerate development by outsourcing MRNA-LNP formulations to a CDMO

RNA-lipid nanoparticle (LNP) vaccines have highlighted the impact of genetic medicines deployed at scale. RNA-LNP applications include gene editing, oncology, and rare diseases.
A common need for these RNA-LNP therapies is a scalable manufacturing process, as development of RNA-LNPs can be time consuming, cost prohibitive and require deep expertise. In a field that is extremely dynamic and accelerating fast, key solutions such as outsourcing can provide direct and valuable access to infrastructure, experience, and meaningful data.
Learn more about BioPharma Services - www.precisionn...
Follow us on LinkedIn: bit.ly/3F9uEiL
Follow us on Twitter: bit.ly/3yBttpW